These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 31096036

  • 1. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
    Ray R, Tombs L, Naya I, Compton C, Lipson DA, Boucot I.
    Pulm Pharmacol Ther; 2019 Aug; 57():101802. PubMed ID: 31096036
    [Abstract] [Full Text] [Related]

  • 2. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
    Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, Patel S, Naya I, Compton C, Alcázar Navarrete B.
    Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
    [Abstract] [Full Text] [Related]

  • 3. Umeclidinium plus vilanterol versus fluticasone propionate plus salmeterol for chronic obstructive pulmonary disease: a meta-analysis of randomized, controlled trials.
    Zhai C, Wang F, Xu R, Sun X, Ma W, Wang L.
    Postgrad Med J; 2024 Sep 22; 100(1188):721-729. PubMed ID: 38652265
    [Abstract] [Full Text] [Related]

  • 4. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
    Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A.
    Respir Med; 2015 Jul 22; 109(7):870-81. PubMed ID: 26006754
    [Abstract] [Full Text] [Related]

  • 5. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
    Ismaila AS, Haeussler K, Czira A, Tongbram V, Malmenäs M, Agarwal J, Nassim M, Živković-Gojović M, Shen Y, Dong X, Duarte M, Compton C, Vogelmeier CF, Halpin DMG.
    Adv Ther; 2022 Nov 22; 39(11):4961-5010. PubMed ID: 35857184
    [Abstract] [Full Text] [Related]

  • 6. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
    Kalberg C, O'Dell D, Galkin D, Newlands A, Fahy WA.
    Drugs R D; 2016 Jun 22; 16(2):217-27. PubMed ID: 27028749
    [Abstract] [Full Text] [Related]

  • 7. Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials.
    Maleki-Yazdi MR, Singh D, Anzueto A, Tombs L, Fahy WA, Naya I.
    Adv Ther; 2017 Jan 22; 33(12):2188-2199. PubMed ID: 27796912
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A.
    Lancet Respir Med; 2014 Jun 22; 2(6):472-86. PubMed ID: 24835833
    [Abstract] [Full Text] [Related]

  • 9. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
    Ismaila AS, Haeussler K, Czira A, Youn JH, Malmenäs M, Risebrough NA, Agarwal J, Nassim M, Sharma R, Compton C, Vogelmeier CF, Han MK, Halpin DMG.
    Adv Ther; 2022 Sep 22; 39(9):3957-3978. PubMed ID: 35849317
    [Abstract] [Full Text] [Related]

  • 10. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
    Moretz C, Sharpsten L, Bengtson LG, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2019 Sep 22; 14():1721-1737. PubMed ID: 31534326
    [Abstract] [Full Text] [Related]

  • 11. Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
    Moretz C, Hahn B, White J, Goolsby Hunter A, Essoi B, Elliott C, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2020 Sep 22; 15():2715-2725. PubMed ID: 33149569
    [Abstract] [Full Text] [Related]

  • 12. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
    Kerwin EM, Kalberg CJ, Galkin DV, Zhu CQ, Church A, Riley JH, Fahy WA.
    Int J Chron Obstruct Pulmon Dis; 2017 Sep 22; 12():745-755. PubMed ID: 28280319
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
    Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A.
    Respir Med; 2014 Dec 22; 108(12):1752-60. PubMed ID: 25458157
    [Abstract] [Full Text] [Related]

  • 14. 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study.
    Lipson DA, Birk R, Brealey N, Zhu CQ.
    Adv Ther; 2020 Dec 22; 37(12):4894-4909. PubMed ID: 33011864
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies.
    Siler TM, Kerwin E, Singletary K, Brooks J, Church A.
    COPD; 2016 Dec 22; 13(1):1-10. PubMed ID: 26451734
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.
    Respir Med; 2015 Sep 22; 109(9):1155-63. PubMed ID: 26117292
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.
    Respir Med; 2013 Oct 22; 107(10):1538-46. PubMed ID: 23830094
    [Abstract] [Full Text] [Related]

  • 18. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
    Rodrigo GJ, Neffen H.
    Chest; 2015 Aug 22; 148(2):397-407. PubMed ID: 25798635
    [Abstract] [Full Text] [Related]

  • 19. Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities.
    Kalhan R, Slade D, Ray R, Moretz C, Germain G, Laliberté F, Shen Q, Duh MS, MacKnight SD, Hahn B.
    Int J Chron Obstruct Pulmon Dis; 2021 Aug 22; 16():1149-1161. PubMed ID: 33911860
    [Abstract] [Full Text] [Related]

  • 20. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β2-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β2-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity Score-Inverse Probability of Treatment Weighting Cohort Study.
    Wang MT, Lai JH, Huang YL, Liou JT, Cheng SH, Lin CW, Pan HY, Hsu YJ, Tsai CL.
    Chest; 2021 Oct 22; 160(4):1255-1270. PubMed ID: 34023320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.